According to Eagle Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $0.25 B. In 2022 the company made a revenue of $0.31 B an increase over the years 2021 revenue that were of $0.17 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.25 B | -18.65% |
2022 | $0.31 B | 84.56% |
2021 | $0.17 B | -8.66% |
2020 | $0.18 B | -4.13% |
2019 | $0.19 B | -8.17% |
2018 | $0.21 B | -9.88% |
2017 | $0.23 B | 24.92% |
2016 | $0.18 B | 186.11% |
2015 | $66.22 M | 244.8% |
2014 | $19.2 M | 8.59% |
2013 | $17.68 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 36,017.90% | ๐บ๐ธ USA |
Novartis NVS | $49.92 B | 19,284.12% | ๐จ๐ญ Switzerland |
Eli Lilly LLY | $34.12 B | 13,149.45% | ๐บ๐ธ USA |
Amgen AMGN | $28.19 B | 10,845.40% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.53 B | 17,579.61% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $37.84 B | 14,595.75% | ๐ฌ๐ง UK |
Teva Pharmaceutical Industries TEVA | $15.84 B | 6,052.57% | ๐ฎ๐ฑ Israel |